“Abrocitinib in the Treatment of Moderate-to-Severe Atopic Dermatitis Refractory to Dupilumab Treatment: An Analysis of JADE-EXTEND, a Phase 3 Long-Term Extension Study”. 2023. SKIN The Journal of Cutaneous Medicine 7 (2): s153. https://doi.org/10.25251/skin.7.supp.153.